MEDIAN Technologies at the University and Polytechnic Hospital La Fe Valencia, Spain
MEDIAN Technologies today announced the new finalization of its LMS applications portfolio installation at Hospital Universitari i Politècnic La Fe in Valencia, Spain.
This installation follows a sale performed as part of a local business action between MEDIANTechnologies and AGFA Healthcare Spain. On-site deployment of LMS solutions has been carried outthrough LMS solutions integration into AGFA Impax PACS (Picture Archiving and Communication System).
The new university hospital of La Fe is now one of the biggest public health structures in Spain and also the most recent one. Open to the public since February 2011, the hospital includes state-of-theart medical equipment platforms, which LMS solutions are now part of.
MEDIAN LMS solutions will be used there in a clinical and translational research context as well as in radiologists’ daily practice, both for the follow-up of cancer patients, and for detection and follow-upof pulmonary lesions in other patients.
« We are very satisfied and proud of this success mainly for three reasons”, Gérard Milhiet, Executive Vice President and Co-founder of MEDIAN reports. “First, we are delighted to be chosen by Hospital La Fe, one of the most impressive medical imaging platforms of Spain. Then, our aim is to contribute with AGFA Healthcare Spain to good practices in pulmonary and oncologic imaging working with the medical team under the aegis of Pr. L. Marti-Bonmati. Finally, from a more technical point of view, we demonstrate once again the great capacity of our LMS clinical applications to be fully integrated into heterogeneous and multi-manufacturer environments”. “We intend to promote this prestigious reference among other health structures in Spain and beyond”, Gérard Milhiet concludes.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”